Natera executive sells 3,000 shares in plan trade

Natera, Inc. president of clinical diagnostics Solomon Moshkevich sold 3,000 shares of common stock in open-market transactions.

Rhea-AI Filing Summary

Natera, Inc. president of clinical diagnostics Solomon Moshkevich sold 3,000 shares of common stock in open-market transactions. The trades on June 1, 2026 were executed under a pre-arranged Rule 10b5-1 trading plan and at various prices. After these sales, he directly holds 137,643 shares.

Insights

Insider trading and governance analyst

Pre-planned, modest open-market sale with large remaining stake.

Solomon Moshkevich, president of clinical diagnostics at Natera, Inc., sold 3,000 shares of common stock in four open-market transactions on June 1, 2026. Reported prices per share include $217.5199, $218.8445, $219.3400, and $220.6674.

The filing states these sales were made under a Rule 10b5-1 trading plan adopted on November 26, 2024, indicating they were pre-scheduled rather than opportunistic. Following the transactions, Moshkevich still holds 137,643 shares directly, suggesting the sale represents only a small portion of his visible equity position.

The weighted-average prices reflect multiple trades within ranges from $217.01 to $220.83 per share. Future company filings may update his holdings if additional plan-related trades occur, but based on this data alone the activity appears routine and not thesis-changing.

Insider Trade Summary 10b5-1

Net Seller: 3,000 shares

Net Sell 4 txns

Insider Moshkevich Solomon

Role PRESIDENT, CLINICALDIAGNOSTICS

Sold 3,000 shs ($655K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,802	$217.5199	$392K
Sale	Common Stock	413	$218.8445	$90K
Sale	Common Stock	213	$219.34	$47K
Sale	Common Stock	572	$220.6674	$126K

Holdings After Transaction: Common Stock — 137,643 shares (Direct)

Footnotes (4)

1. F1. The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.
2. F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.01 to $218.00 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.2250 to $219.0900 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.52 to $220.83 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 3,000 shares Price per share (block 1): $217.5199 per share Price per share (block 2): $218.8445 per share +5 more

8 metrics

Shares sold 3,000 shares Total common shares sold on June 1, 2026

Price per share (block 1) $217.5199 per share Weighted-average sale price for 1,802 shares

Price per share (block 2) $218.8445 per share Weighted-average sale price for 413 shares

Price per share (block 3) $219.3400 per share Weighted-average sale price for 213 shares

Price per share (block 4) $220.6674 per share Weighted-average sale price for 572 shares

Post-transaction holdings 137,643 shares Common stock held directly after reported sales

Low trade range $217.01 per share Lowest sale price within disclosed trade ranges

High trade range $220.83 per share Highest sale price within disclosed trade ranges

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, beneficial ownership

4 terms

Rule 10b5-1 trading plan regulatory

"The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The reported price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

beneficial ownership financial

"The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Natera (NTRA) report for Solomon Moshkevich?

Natera reported that executive Solomon Moshkevich sold 3,000 shares of common stock on June 1, 2026. The open-market sales were broken into four transactions at weighted-average prices between about $217 and $221 per share, according to the Form 4 filing.

At what prices were the Natera (NTRA) insider shares sold?

The Form 4 lists weighted-average sale prices of $217.5199, $218.8445, $219.3400, and $220.6674 per share. Footnotes explain each figure represents multiple trades within narrower ranges from $217.01 up to $220.83 per share, with full trade details available on request.

How many Natera (NTRA) shares does Solomon Moshkevich still own after the sale?

After selling 3,000 shares, Solomon Moshkevich directly holds 137,643 shares of Natera common stock. This post-transaction holding, disclosed in the Form 4, indicates that the reported sale represents only a small fraction of his remaining direct ownership stake.

Was the June 2026 Natera (NTRA) insider sale made under a Rule 10b5-1 plan?

Yes. A footnote states the June 1, 2026 sales were effected under a Rule 10b5-1 trading plan adopted on November 26, 2024. Such pre-arranged plans automate trades over time, reducing the significance of day-to-day timing decisions by the executive.

Who is the insider involved in the latest Natera (NTRA) Form 4?

The Form 4 lists Solomon Moshkevich, Natera’s president of clinical diagnostics, as the reporting person. He executed four open-market sales totaling 3,000 shares and now directly holds 137,643 shares of Natera common stock after the reported transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 09:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moshkevich Solomon

(Last) (First) (Middle)

C/O NATERA, INC.

13011 MCCALLEN PASS BUILDING A SUITE 100

(Street)

AUSTIN TEXAS 78753

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Natera, Inc. [ NTRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT, CLINICALDIAGNOSTICS

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		S		1,802(1)	D	$217.5199(2)	138,841	D
Common Stock	06/01/2026		S		413(1)	D	$218.8445(3)	138,428	D
Common Stock	06/01/2026		S		213(1)	D	$219.34	138,215	D
Common Stock	06/01/2026		S		572(1)	D	$220.6674(4)	137,643	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.01 to $218.00 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.2250 to $219.0900 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.52 to $220.83 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Tami Chen, Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)